Drug
BAY2328065
BAY2328065 is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_1
BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect
NCT03427788
completedphase_1
A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants
NCT04851483
Clinical Trials (2)
Showing 2 of 2 trials
NCT03427788Phase 1
BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect
NCT04851483Phase 1
A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2